- Home
- RMD
RMD
ResMed Inc.
as of 08-26-2026 3:46pm EST
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 32.4B | IPO Year: | 1996 |
| Target Price: | $292.56 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | monthly | |
| EPS: | 10.43 | EPS Growth: | 9.67 |
| 52 Week Low/High: | $180.26 - $284.87 | Next Earning Date: | 04-30-2026 |
| Revenue: | $2,957,013,000 | Revenue Growth: | 13.44% |
| Revenue Growth (this year): | 10.6% | Revenue Growth (next year): | 7.41% |
| P/E Ratio: | 22.68 | Index: | |
| Free Cash Flow: | 1.6B | FCF Growth: | +28.73% |
Stock Insider Trading Activity of ResMed Inc. (RMD)
Chairman and CEO
Avg Cost/Share
$205.69
Shares
4,991
Total Value
$1,026,596.29
Owned After
466,256
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Farrell Michael J. | RMD | Chairman and CEO | Aug 7, 2026 | Sell | $205.69 | 4,991 | $1,026,596.29 | 466,256 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K SELL Aug 6, 2026 · 100% conf.
Q2 2026 Earnings
8-K SELLAug 6, 2026 · 100% conf.
1D
-4.31%
$213.61
Act: -5.06%
5D
-5.78%
$210.34
Act: +1.57%
20D
-4.09%
$214.11
Transcript text not available. View on SEC.gov →
2026 Q2 Q2 2026 Earnings
8-K SELL Jul 7, 2026 · 100% conf.
Q2 2026 Earnings
8-K SELLJul 7, 2026 · 100% conf.
1D
-4.31%
$213.61
Act: -5.06%
5D
-5.78%
$210.34
Act: +1.57%
20D
-4.09%
$214.11
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K Apr 30, 2026
Q1 2026 Earnings
8-KApr 30, 2026
Compare RMD vs Leading Stocks
See how RMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RMD ResMed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.